{"meta":{"query_hash":"a23204d1ea13","filters":{"venue":"AME Clinical Trials Review"},"cohort_total":5,"direct_labels_cover":0,"predictions_cover":5,"exported":5,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a23204d1ea13","api":"https://metacan.xera.ac/api/v1/cohort?venue=AME+Clinical+Trials+Review"},"results":[{"id":"W4392735304","doi":"10.21037/actr-23-42","title":"CheckMate 817: expanding the pool of patients eligible for immune checkpoint inhibitor therapy in advanced non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Immune checkpoint; Oncology; Immune system; Immunotherapy; Cancer research; Internal medicine; Immunology","score_opus":0.12454750418736286,"score_gpt":0.47863540940110255,"score_spread":0.3540879052137397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392735304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36780593,0.5270071,0.0030239492,0.044100776,0.006446497,0.0028882148,0.005682973,0.00040023585,0.04264432],"genre_scores_gemma":[0.72790956,0.20772214,0.0044116313,0.03687769,0.0026285308,0.0022798728,0.0063177366,0.00009154729,0.011761287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946254,0.0002602321,0.000040642677,0.00006878782,0.000087950255,0.00007988435],"domain_scores_gemma":[0.99890316,0.0005972891,0.00015304326,0.000026021036,0.00011087365,0.00020967449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021136336,0.00029685348,0.0015146572,0.00047627973,0.00023468473,0.0012917892,0.00075379765,0.0007996469,0.008633564],"category_scores_gemma":[0.0034043463,0.00013941283,0.0015791068,0.0004558666,0.00026452445,0.0010532095,0.00084801484,0.0018720707,0.0009827628],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03130756,0.0009861724,0.006634314,0.0068188747,0.0013876815,0.000096524,0.00010990803,0.001659709,0.0031827264,0.003233345,0.059415024,0.8851682],"study_design_scores_gemma":[0.18065196,0.060182497,0.111823365,0.014395455,0.008733708,0.0012735209,0.00053886464,0.0064885896,0.004381841,0.011534555,0.59979385,0.00020192369],"about_ca_topic_score_codex":0.00086781435,"about_ca_topic_score_gemma":0.0044308,"teacher_disagreement_score":0.008633564,"about_ca_system_score_codex":0.0008433251,"about_ca_system_score_gemma":0.0011151752,"threshold_uncertainty_score":0.028882086},"labels":[],"label_agreement":null},{"id":"W4401922562","doi":"10.21037/actr-24-34","title":"Chemo-immunotherapy on localized gastroesophageal/gastric adenocarcinoma—hope or delusion?","year":2024,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Delusion; Immunotherapy; Gastroesophageal Junction; Cancer; Medicine; Adenocarcinoma; Internal medicine; Gastroenterology; Psychiatry","score_opus":0.2471063106414863,"score_gpt":0.5112828568609188,"score_spread":0.2641765462194325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401922562","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006174112,0.99409074,0.00005781698,0.0037530973,0.0006159159,0.000025354977,0.000046442674,0.0000035088458,0.0007897186],"genre_scores_gemma":[0.012077662,0.97294235,0.00043914307,0.011612156,0.0017406128,0.00009339773,0.00011216194,0.00000587006,0.0009766999],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988582,0.0006029167,0.00020969164,0.000081778344,0.00015994757,0.00008745108],"domain_scores_gemma":[0.9961526,0.0024108763,0.00064190174,0.00007363135,0.00053880614,0.00018223797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052072606,0.00051264866,0.0032794103,0.00077038055,0.00026913354,0.0021631205,0.0009096689,0.0018099707,0.0052847317],"category_scores_gemma":[0.006889367,0.00028308472,0.0022908747,0.0011409726,0.00062067516,0.0017333382,0.0006626346,0.0029050068,0.0008104974],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005492407,0.0002337572,0.0009572593,0.069988824,0.00345731,0.00012236857,0.000110063826,0.00038033162,0.0015270035,0.0043718456,0.05593126,0.85742754],"study_design_scores_gemma":[0.010713173,0.008027366,0.006282074,0.10118471,0.015676891,0.0008930534,0.0003653482,0.00045400774,0.00090925326,0.005418591,0.84999144,0.00008404708],"about_ca_topic_score_codex":0.0008645806,"about_ca_topic_score_gemma":0.003810993,"teacher_disagreement_score":0.0052847317,"about_ca_system_score_codex":0.0008192366,"about_ca_system_score_gemma":0.0017661756,"threshold_uncertainty_score":0.027538955},"labels":[],"label_agreement":null},{"id":"W4403847447","doi":"10.21037/actr-24-101","title":"A new ALK inhibitor is not a game changer, but an older one is!","year":2024,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Computer science","score_opus":0.40507471595213795,"score_gpt":0.5887407088941433,"score_spread":0.18366599294200536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403847447","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005938994,0.8861964,0.0009649058,0.08942714,0.016338037,0.00008519158,0.00028949877,0.00007929377,0.0060257115],"genre_scores_gemma":[0.009233432,0.82727325,0.004003111,0.13001667,0.016698949,0.00018848671,0.00046763913,0.00008922011,0.0120292585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976949,0.0009158702,0.00036084294,0.0002490599,0.0006161094,0.00016321836],"domain_scores_gemma":[0.9895167,0.006176071,0.0010979937,0.00028034466,0.0022291539,0.0006997654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008264787,0.000838477,0.0030008287,0.0011605887,0.0005192638,0.0033050634,0.0016183786,0.003573199,0.014165985],"category_scores_gemma":[0.014087946,0.00040876845,0.0032766995,0.0010131723,0.0011598996,0.0063521233,0.0009476534,0.008057806,0.0050925193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013872359,0.0001696739,0.00022260525,0.016822115,0.00091612426,0.00014392253,0.00008411757,0.00023019954,0.0015931556,0.012662621,0.33617586,0.62959236],"study_design_scores_gemma":[0.00084327813,0.0008258607,0.0005732306,0.012994986,0.00093165,0.0002866846,0.000089989604,0.00009445789,0.00020860726,0.00635919,0.9767461,0.000046025394],"about_ca_topic_score_codex":0.0017233258,"about_ca_topic_score_gemma":0.005794783,"teacher_disagreement_score":0.014165985,"about_ca_system_score_codex":0.0011643048,"about_ca_system_score_gemma":0.0024112873,"threshold_uncertainty_score":0.047389984},"labels":[],"label_agreement":null},{"id":"W4403847681","doi":"10.21037/actr-24-44","title":"Utilizing therapeutic response as a criterion for PARP inhibitor maintenance therapy in advanced triple negative breast cancer; promoting personalized medicine","year":2024,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Triple-negative breast cancer; PARP inhibitor; Breast cancer; Oncology; Medicine; Internal medicine; Cancer; Poly ADP ribose polymerase; Biology; Genetics","score_opus":0.317957896190338,"score_gpt":0.5660474151581424,"score_spread":0.2480895189678044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403847681","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013304923,0.9692415,0.0037303509,0.005153423,0.0009120801,0.00088331255,0.0004078289,0.000041014944,0.0063254694],"genre_scores_gemma":[0.23869178,0.7198765,0.021623945,0.011411285,0.0024435623,0.0017601637,0.0009654159,0.00004356991,0.0031836813],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962365,0.0022611006,0.00055029074,0.00025252983,0.0005956835,0.00010390425],"domain_scores_gemma":[0.99029094,0.0064316904,0.0017300526,0.00026362963,0.0011187873,0.00016496828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013498328,0.0006760229,0.00272998,0.0013012926,0.00024109712,0.0019349682,0.0008012044,0.0010965609,0.001993001],"category_scores_gemma":[0.014870333,0.00024993284,0.0018265593,0.0013439602,0.000497755,0.0010860654,0.00057502394,0.0027393117,0.00039853077],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060317423,0.00051544106,0.004947245,0.025731016,0.0029039676,0.000076685326,0.000109152425,0.001133626,0.005403842,0.0041081985,0.009675864,0.9393633],"study_design_scores_gemma":[0.014683613,0.049680207,0.06321202,0.0563259,0.03681437,0.0028120035,0.00053578714,0.008317818,0.02090471,0.011697384,0.734697,0.00031922117],"about_ca_topic_score_codex":0.0006053451,"about_ca_topic_score_gemma":0.002236795,"teacher_disagreement_score":0.013498328,"about_ca_system_score_codex":0.001319401,"about_ca_system_score_gemma":0.0016471486,"threshold_uncertainty_score":0.071386814},"labels":[],"label_agreement":null},{"id":"W4407980374","doi":"10.21037/actr-24-168","title":"Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial","year":2025,"lang":"en","type":"article","venue":"AME Clinical Trials Review","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Unpacking; Prostate-specific antigen; Dynamics (music); Prostate; Psychology; Medicine; Internal medicine; Pedagogy","score_opus":0.18674173293153118,"score_gpt":0.4727159903833336,"score_spread":0.28597425745180244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407980374","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022488996,0.94979227,0.0013070226,0.017079929,0.0012883432,0.00017750984,0.0016664236,0.000030167796,0.006169315],"genre_scores_gemma":[0.33025587,0.6360025,0.003729958,0.01899677,0.0050964565,0.00061381795,0.0029577196,0.00010801919,0.0022388939],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9823497,0.014114617,0.0011352451,0.0006311117,0.001330654,0.00043865817],"domain_scores_gemma":[0.9447129,0.04624559,0.0047872243,0.0018742802,0.0017629236,0.0006171426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03499696,0.0008761579,0.0041389316,0.00076719146,0.00027329035,0.0027856724,0.0012295265,0.0017563483,0.0053062118],"category_scores_gemma":[0.06805817,0.00037530746,0.004488977,0.002355566,0.0009962104,0.0021547116,0.0011856784,0.0046173017,0.00064028404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06296394,0.0005857028,0.02670216,0.04420218,0.07620566,0.00020676032,0.00046396535,0.0044931485,0.0010038108,0.02318569,0.049146328,0.7108405],"study_design_scores_gemma":[0.07891695,0.022204624,0.1630393,0.061456352,0.14308584,0.0013031336,0.001015979,0.0043153916,0.0017393572,0.08700957,0.4352539,0.0006596252],"about_ca_topic_score_codex":0.0024877067,"about_ca_topic_score_gemma":0.0055047013,"teacher_disagreement_score":0.03499696,"about_ca_system_score_codex":0.0011644994,"about_ca_system_score_gemma":0.0033477703,"threshold_uncertainty_score":0.1850838},"labels":[],"label_agreement":null}]}